CAP--advancing the evaluation of preclinical Alzheimer disease treatments

Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.


If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics
  • Cognitive Dysfunction / diagnosis
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / genetics
  • Cooperative Behavior
  • Disease Progression
  • Drug Evaluation, Preclinical
  • Early Diagnosis
  • Guideline Adherence
  • Humans
  • Interdisciplinary Communication
  • Neuropsychological Tests
  • Nootropic Agents / therapeutic use
  • Prodromal Symptoms*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome


  • Nootropic Agents